$KSEZ
Kinetic Seas Inc.

2024 Q2 Form 10-K Financial Statement

#000168316824002276 Filed on April 10, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2023 Q4 2023
Revenue $61.77K $0.00
YoY Change
Cost Of Revenue $46.42K $0.00
YoY Change
Gross Profit $15.35K $0.00
YoY Change
Gross Profit Margin 24.85%
Selling, General & Admin $253.3K $121.5K
YoY Change 1040.92% 60.65%
% of Gross Profit 1650.11%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $185.00
YoY Change
% of Gross Profit
Operating Expenses $458.2K $121.5K
YoY Change 1963.56% 60.65%
Operating Profit -$442.9K -$121.5K
YoY Change 1894.42% 60.65%
Interest Expense $39.42K
YoY Change 113.36%
% of Operating Profit
Other Income/Expense, Net -$14.72K -$39.42K
YoY Change 73.42% 113.36%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$457.6K -$161.0K
YoY Change 1390.74% 71.0%
Net Earnings / Revenue -740.77%
Basic Earnings Per Share -$0.02 -$0.03
Diluted Earnings Per Share -$0.02 -$0.03
COMMON SHARES
Basic Shares Outstanding 31.15M shares 3.046M shares 4.353M shares
Diluted Shares Outstanding 24.09M shares 4.353M shares

Balance Sheet

Concept 2024 Q2 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $60.23K $17.93K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables $20.04K $0.00
Other Receivables
Total Short-Term Assets $90.28K $17.93K
YoY Change 1665.94% 1203.13%
LONG-TERM ASSETS
Property, Plant & Equipment $103.0K $13.14K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $103.0K $13.14K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $90.28K $17.93K
Total Long-Term Assets $103.0K $13.14K
Total Assets $193.3K $31.07K
YoY Change 3680.71% 2158.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $24.70K $0.00
YoY Change 123.91% -100.0%
Accrued Expenses $241.0K $33.49K
YoY Change 619.66% 0.0%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $578.5K $226.6K
YoY Change 190.3% 43.84%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $578.5K $226.6K
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$1.775M -$1.118M
YoY Change 78.39% 16.82%
Common Stock $165.00 $266.00
YoY Change 450.0% -81.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$385.2K -$195.5K
YoY Change
Total Liabilities & Shareholders Equity $193.3K $31.07K
YoY Change 3680.71% 2158.14%

Cashflow Statement

Concept 2024 Q2 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$457.6K -$161.0K
YoY Change 1390.74% 71.0%
Depreciation, Depletion And Amortization $185.00
YoY Change
Cash From Operating Activities -$133.7K
YoY Change 111.29%
INVESTING ACTIVITIES
Capital Expenditures $13.33K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$13.33K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $71.60K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $163.6K
YoY Change 172.67%
NET CHANGE
Cash From Operating Activities -$133.7K
Cash From Investing Activities -$13.33K
Cash From Financing Activities $163.6K
Net Change In Cash $16.56K
YoY Change -603.65%
FREE CASH FLOW
Cash From Operating Activities -$133.7K
Capital Expenditures $13.33K
Free Cash Flow -$147.0K
YoY Change 132.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001945619
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Schaumburg
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
IL
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
60173
CY2023 dei City Area Code
CityAreaCode
(888)
CY2023 dei Local Phone Number
LocalPhoneNumber
901-8806
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
180600 usd
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31146000 shares
CY2023 dei Auditor Name
AuditorName
BF Borgers CPA PC
CY2023 dei Auditor Firm
AuditorFirmId
5041
CY2023 dei Auditor Location
AuditorLocation
Lakewood, CO
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1376 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1376 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 usd
CY2022Q4 us-gaap Assets
Assets
1376 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
0 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12366 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33486 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33486 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
11098 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
21674 usd
CY2023Q4 ECGR Notes Payable Related Parties Current
NotesPayableRelatedPartiesCurrent
182000 usd
CY2022Q4 ECGR Notes Payable Related Parties Current
NotesPayableRelatedPartiesCurrent
90000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
226584 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
157526 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26646000 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26646000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3046000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3046000 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
266 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
30 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
922020 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
800656 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1117798 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-956835 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-195512 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-156149 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31072 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1376 usd
CY2023 us-gaap Revenues
Revenues
0 usd
CY2022 us-gaap Revenues
Revenues
0 usd
CY2023 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2023 us-gaap Gross Profit
GrossProfit
0 usd
CY2022 us-gaap Gross Profit
GrossProfit
0 usd
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
121538 usd
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
75653 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
75653 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-75653 usd
CY2022 us-gaap Interest Expense
InterestExpense
18478 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-18478 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-94131 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4352849 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4352849 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-62018 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-94131 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-156149 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-156149 usd
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
71600 usd
CY2023 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
50000 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-160962 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-195512 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-160962 usd
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
185 usd
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
0 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
12366 usd
CY2023 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
39424 usd
CY2022 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
18478 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-63287 usd
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
CY2022 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
60000 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
60000 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3287 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4663 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1376 usd
CY2023 ECGR Reduction Of Accrued Interest With Common Stock
ReductionOfAccruedInterestWithCommonStock
50000 usd
CY2022 ECGR Reduction Of Accrued Interest With Common Stock
ReductionOfAccruedInterestWithCommonStock
0 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_844_eus-gaap--UseOfEstimates_zLBnODrFMiC7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><span style="text-decoration: underline">Use of Estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of accrued liabilities and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to revenue recognition, valuation of accounts receivable and the allowance for doubtful accounts, inventories, and contingencies. The Company bases its estimates on historical experience, known or expected trends, and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1376 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1117798 usd
CY2023Q4 ECGR Working Capital
WorkingCapital
-208563 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33486 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
33486 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26646000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3046000 shares
CY2023Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
reverse split of 1 for 100
CY2023 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001683168-24-002276-index-headers.html Edgar Link pending
0001683168-24-002276-index.html Edgar Link pending
0001683168-24-002276.txt Edgar Link pending
0001683168-24-002276-xbrl.zip Edgar Link pending
ecgr-20231231.xsd Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
image_002.jpg Edgar Link pending
image_008.jpg Edgar Link pending
image_009.jpg Edgar Link pending
image_013.jpg Edgar Link pending
image_014.jpg Edgar Link pending
image_017.jpg Edgar Link pending
image_018.jpg Edgar Link pending
image_019.jpg Edgar Link pending
image_020.jpg Edgar Link pending
ecgr-20231231_def.xml Edgar Link unprocessable
ecgr-20231231_lab.xml Edgar Link unprocessable
ecgr-20231231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
kinetic_ex0303.htm Edgar Link pending
kinetic_ex0306.htm Edgar Link pending
kinetic_ex0307.htm Edgar Link pending
kinetic_ex0308.htm Edgar Link pending
kinetic_ex0401.htm Edgar Link pending
kinetic_ex0402.htm Edgar Link pending
kinetic_ex14.htm Edgar Link pending
kinetic_ex3101.htm Edgar Link pending
kinetic_ex3201.htm Edgar Link pending
kinetic_i10k-123123.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ecgr-20231231_cal.xml Edgar Link unprocessable
kinetic_i10k-123123_htm.xml Edgar Link completed